FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, is pleased to announce the appointment of Samuel Hernandez, Ph.D., as senior vice president and site head for its College Station, Texas facility, effective Monday, August 25. With over two decades of biotechnology and pharmaceutical leadership experience, Dr. Hernandez is poised to lead the Texas site’s approximately 770-strong team to achieve continued growth of cell culture and advanced therapies offerings. The previous site head, Keita Hirabayashi, has been appointed to the position of senior director, Corporate Office and board member of the Texas site.

Dr. Hernandez joins FUJIFILM Biotechnologies from Amgen, where he recently served as executive director and head of Global Manufacturing Strategies and Technologies. In this role, he contributed to the strategy for manufacturing capacity expansion and integrated cutting-edge technologies across sites in the U.S., Puerto Rico, Europe, and Asia. His tenure as plant manager at Amgen's Juncos, Puerto Rico, site was marked by operational transformation, including the successful introduction of new products and critical partnerships, notably manufacturing a COVID-19 neutralizing antibody therapy. Dr. Hernandez has a Ph.D. in Molecular Biophysics and Biochemistry from Yale University and a B.S. in Chemistry from the University of Puerto Rico.

In his new role, Dr. Hernandez will oversee Texas site strategy, operations, talent development, and uphold FUJIFILM Biotechnologies' commitment to quality, innovation, and reliable supply for its partners.

“We are thrilled to have Sam join our team to lead our Texas site during an exciting period where we are supporting treatments to combat serious diseases such as cancers,” said Lars Petersen, president and chief executive officer, FUJIFILM Biotechnologies. “His commitment to quality and our People First culture will enable us to continue our growth journey at this site.”

“I am grateful for the opportunity to join FUJIFILM Biotechnologies, a brand with a history of innovation and excellence in manufacturing,” said Dr. Hernandez. “I am truly excited about the opportunity to lead the talented team here in Texas.”

About FUJIFILM Biotechnologies

FUJIFILM Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines and advanced therapies. With over 30 years of experience, the Company specializes in developing and manufacturing biopharmaceuticals using microbial, mammalian, and host/virus systems. With over 4,800 employees, FUJIFILM Biotechnologies operates a fully integrated, kojoX^TM global network with major facilities in the United States, the United Kingdom, and Denmark, with a planned new site in Holly Springs, North Carolina, USA. The Company's kojoX manufacturing network ensures supply chain agility for its customers through modular facilities and standardized processes for seamless scaling and technology transfers. FUJIFILM Biotechnologies offers comprehensive services, ranging from proprietary cell line development, to process and analytical development, and through to clinical and commercial manufacturing. For more information, go to: fujifilmbiotechnologies.fujifilm.com

About FUJIFILM Holdings Corporation

FUJIFILM Corporation is a subsidiary of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of “giving our world more smiles,” we address social challenges and create a positive impact on society through our products, services, and business operations. For more information, please visit: www.fujifilmholdings.com. For further details about our commitment to sustainability and Fujifilm’s Sustainable Value Plan 2030, click here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250904990610/en/